(The Forbes profile says Mr. Bowman is 74 years old,
so although things look pretty bleak right now in
terms of the shareprice and marketcap and that,
this could just be part of retirement.)
On May 14, 2008, Jack L. Bowman notified Targeted Genetics of his resignation as a member of the board of directors of Targeted Genetics effective May 15, 2008. Mr. Bowman's decision to resign is not related to any disagreement with Targeted Genetics or its management on any matter relating to its operations, policies or practices.
Prior to his resignation, Mr. Bowman served as the chairman of the compensation committee of the board of directors and served on the Targeted Genetics board of directors since March 1997. Targeted Genetics greatly appreciates Mr. Bowman's service as a director and thanks him for his leadership contributions during that time.
Pretty tough owning this stock for the past decade, although
I suppose they get shares, they sell, they get more, they sell.
--------------------
More important to TGEN right now is whether their expertise
with AAV can be used for any new projects, or is this
a platform that just isn't going to be useful. And especially
whether the arthritis program has enough promise to
perhaps pick up a partner and continue clinical trials.
Also, if I go to the annual meeting, I might ask Parker whether
the vaccine work is on the back burner--since she didn't
mention it in the R&R presentation, I wonder about that.
Huntington's ought to be offloaded to a new outfit like
Ceregene--obviously they have enough projects and not enough
money to persue more than one or two for the next year. Then
poof I guess after that anyway. |
